Oral Antidiabetic Agents - Luzimar Teixeira

More documents

Recommendations

Info

410 Krentz & Bailey References 23. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223-41 1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with convensevere refractory sulfonylurea-induced hypoglycemia with oc- 24. Krentz AJ, Boyle PJ, Justice K, et al. Successful treatment of tional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53 treotide. Diabetes Care 1993; 16: 184-6 2. European Diabetes Policy Group. A desktop guide to type 2 25. Wilson SH, Kennedy FP, Garratt KN. Optimisation of the diabetes mellitus. Diabetic Med 1999; 16: 716-30 management of patients with coronary heart disease and type 2 diabetes mellitus. Drugs Aging 2001; 18: 325-33 3. Tuomilheto J. Controlling glucose and blood pressure in type 2 diabetes. BMJ 2000; 321: 394-6 26. Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and 4. Krentz AJ, Bailey CJ. Type 2 diabetes in practice. London: glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004; Royal Society of Medicine Press, 2001 34: 535-42 5. Adler AI. Cardiovascular risk reduction in diabetes: underemphasized and overdue: messages from major trials. Clin 27. Landgraf R. Meglitinide analogues in the treatment of type 2 Med 2001; 1: 472-7 diabetes mellitus. Drugs Aging 2000; 17 (5): 411-25 6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclero- 28. Dornhorst A. Insulotropic meglitinide analogues. Lancet 2001; sis: epidemiology, pathophysiology and management. JAMA 358: 1709-15 2002; 287: 2570-81 29. Davies M. Nateglinide: better post-prandial glucose control. 7. Gray A, Clarke P, Farmer A, et al. Implementing intensive Prescriber 2002; 13: 17-27 control of blood glucose concentration and blood pressure in 30. Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hypertype 2 diabetes in England: cost analysis. United Kingdom glycaemia is associated with premature death and macrovascu- Prospective Diabetes Study (UKPDS) Group. BMJ 2002; 325: lar complications. Diabetologia 2002; 46 Suppl. 1: M17-21 860-3 31. Lebovitz HE. α-Glucosidase inhibitors as agents in the treat- 8. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention ment of diabetes. Diabetes Revs 1998; 6: 132-45 and cardiovascular disease in patients with type 2 diabetes. N 32. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for the Engl J Med 2003; 348: 383-93 prevention of diabetes mellitus: the STOP-NIDDM random- 9. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, ised trial. STOP-NIDDM Trial Research Group. Lancet 2002; sulfonylurea, metformin, or insulin in patients with type 2 359: 2072-7 diabetes mellitus: progressive requirements for multiple theratrial 33. Holman RR, Cull CA, Turner RC. A randomised double-blind pies. JAMA 1999; 281: 2005-12 of acarbose in type 2 diabetes shows improved glycemic 10. Evans AJ, Krentz AJ. Benefits and risks of transfer from oral control over 3 years (UK Prospective Diabetes Study 44). antidiabetic agents to insulin in type 2 diabetes. In: Krentz AJ, Diabetes Care 1999; 22: 960-4 editor. Drug treatment of type 2 diabetes. Auckland: Adis 34. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and Books, 2000: 85-101 the risk of cardiovascular disease and hypertension in patients 11. Seltzer HS. A summary of criticisms of the findings and conclu- with impaired glucose tolerance: the STOP-NIDDM trial. The sions of the University Group Diabetes Program. Diabetes STOP-NIDDM Trial Research Group. JAMA 2003; 290: 1972; 21: 976-9 486-94 12. Krentz AJ. Sulfonylureas in the prevention of vascular compliprevention 35. Scheen A. Is there a role for alpha-glucosidase inhibitors in the cations: from UKPDS to the ADVANCE study. Proceedings of type 2 diabetes mellitus? Drugs 2003; 63 (10): of the VIIIth European symposium on metabolism. Amster- 933-51 dam: Elsevier Science International Congress Series 1253; 36. Reaven GM. Role of insulin resistance in human disease. Diabe- 2003: 261-77 tes 1988; 37: 1595-607 13. Evans AJ, Krentz AJ. Glimepiride: a new sulphonylurea. Prescriber 37. Krentz AJ. Insulin resistance. Oxford: Blackwell Science, 2002 1999; 10: 51-8 38. Ginsberg HN. Insulin resistance and cardiovascular disease. J 14. Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and Clin Invest 2000; 106: 453-8 insulin secretion: their role in health and disease. Diabetologia 39. Campbell IW. Antidiabetic drugs past and future: will improv- 1999; 42: 903-19 ing insulin resistance benefit cardiovascular risk in type 2 15. Gribble FM, Reimann F. Pharmacological modulation of KATP diabetes mellitus? Drugs 2000; 60 (5): 1017-28 channels. Biochem Soc Trans 2002; 30: 333-9 40. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 16. Rorsman P, Renstrom E. Insulin granule dynamics in pancreatic 574-9 beta cells. Diabetologica 2003; 46: 1029-45 41. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an up- 17. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: date. Ann Intern Med 2002; 137: 25-33 1737-54 42. Cusi K, DeFronzo RA. Metformin: a review of its metabolic 18. Rendell M. The role of sulfonylureas in the management of type effects. Diabetes Rev 1998; 6: 89-131 2 diabetes. Drugs 2004; 64 (12): 1339-58 43. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein 19. Bailey CJ, Day C. Antidiabetic drugs. Br J Cardiol 2003; 10: kinase in the mechanism of action of metformin. J Clin Invest 128-36 2001; 108: 1167-74 20. Yki-Järvinen H. Combination therapies with insulin in type 2 44. Winder WW, Hardie DG. AMP-activated protein kinase, a diabetes. Diabetes Care 2001; 24: 758-67 metabolic master switch: possible roles in type 2 diabetes. Am 21. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. J Physiol 1999; 277: E1-E10 Ann Intern Med 1999; 131: 281-303 45. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic 22. Lebovitz HE. Insulin secretagogues: old and new. Diabetes ovary syndrome: systematic review and meta-analysis. BMJ Revs 1999; 7: 139-53 2003; 327: 951-5 © 2005 Adis Data Information BV. All rights reserved. Drugs 2005; 65 (3)
Oral Antidiabetic Agents 411 46. Howlett HCS, Bailey CJ. A risk-benefit assessment of metfor- 62. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, min in type 2 diabetes mellitus. In: Krentz AJ, editor. Drug fluid retention, and congestive heart failure: a consensus statetreatment of type 2 diabetes. Auckland: Adis Books, 2000: ment from the American Heart Association and the American 61-76 Diabetes Association. Circulation 2003; 108: 2941-8 47. UK Prospective Diabetes Study Group. Effect of intensive 63. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhyblood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet poglycemic effects of thiazolidinediones. Ann Intern Med 1998; 352: 854-65 2001; 134: 61-71 48. The Oxford Centre for Diabetes, Endocrinology and Metabol- 64. Yki-Järvinen H. Thiazolidinedions. N Engl J Med 2004; 351: ism: Diabetes Trials Unit. UK Prospective Diabetes Study 1106-18 [online]. Available from URL: http://www.dtu.ox.ac.uk/ 65. Marten FMAC, Visseren FLJ, Lemay J, et al. Metabolic and ukpds/index.html [Accessed 2004 Nov 23] additional vascular effects of thiazolidinediones. Drugs 2002; 49. Hermann LS, Lindberg G, Lindblad U, et al. Efficacy, effec- 62 (10): 1463-80 tiveness and safety of sulphonylurea-metformin combination 66. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of therapy in patients with type 2 diabetes. Diabetes Obes Metab 2002; 4: 296-304 pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk 50. Johnson JA, Majumdar SR, Simpson SH, et al. Decreased hispanic women. Diabetes 2002; 51: 2796-803 mortality associated with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-8 67. Bell DSH. B-cell rejuvenation with thiazolidinediones. Am J Med 2003; 115 (8A): 20-23S 51. Diabetes Prevention Program Research Group. Reduction of the incidence of type 2 diabetes with lifestyle intervention or 68. Roberts AW, Thomas A, Rees A, et al. Peroxisome proliferator metformin. N Engl J Med 2002; 346: 393-403 activated receptor-γ agonists in atherosclerosis: current evidence and future directions. Curr Opin Lipidol 2003; 14: 52. Sulkin T, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997; 20: 567-73 925-8 69. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 53. Holt HB, Krentz AJ. Metabolic emergencies in type 2 diabetes. 2000; 355: 1008-10 In: Goldstein B, Müller-Wieland D, editors. Textbook of type 70. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabe- 2 diabetes. London: Martin Dunitz, 2003: 183-98 tes. JAMA 2002; 287: 360-72 54. Lalau J-D, Race J-M. Metformin and lactic acidosis in diabetic 71. Kendall H. Trends in prescribing of drugs used to treat diabetes. humans. Diabetes Obes Metab 2000; 2: 131-7 Prescriber 2003; 14 (24): 38-9 55. Day C. Thiazolidinediones: a new class of antidiabetic drugs. 72. Cuthbertson D, Leese G. Managing type 2 diabetes: oral an- Diabetic Med 1999; 16: 1-14 tidiabetic drugs. Prescriber 2003; 14 (13): 47-53 56. Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 73. Bell DSH. Type 2 diabetes mellitus: what is the optimal treat- 2 diabetes. BMJ 2000; 321: 252-3 ment regimen? Am J Med 2004; 116 (5A): 23S-9S 57. Rosen ED, Spiegelman BM. PPAR-γ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 74. Kaufman FR. Type 2 diabetes mellitus in children and youth: a 2001; 276: 37731-4 new epidemic. J Pediatr Endocrinol Metab 2002; 15 Suppl. 2: 737-44 58. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003; 46: 1594-1603 75. Huizar JF, Gonzalez LA, Alderman J, et al. Sulfonylureas attenuate electrocardiographic ST-segment elevation during a 59. Baldwin SJ, Clarke SE, Chenery RJ. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism myocardial infarction. J Am Coll Cardiol 2003; 42: 1017-21 of rosiglitazone. Br J Clin Pharmacol 1999; 48: 424-32 60. Bailey CJ, Day C, Krentz AJ. Nice timing for glitazones. Br J Diabetes Vasc Dis 2003; 3: 366-7 61. Buch HN, Baskar V, Barton DM, et al. Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes. Diabetic Med 2002; 19: 572-4 Correspondence and offprints: Dr Andrew J. Krentz, Mailpoint 47, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK. E-mail: a.j.krentz@soton.ac.uk © 2005 Adis Data Information BV. All rights reserved. Drugs 2005; 65 (3)
Page 1 and 2: Drugs 2005; 65 (3): 385-411 REVIEW
Page 3 and 4: Oral Antidiabetic Agents 387 haemog
Page 5 and 6: Oral Antidiabetic Agents 389 obese,
Page 7 and 8: Oral Antidiabetic Agents 391 Glucos
Page 9 and 10: Oral Antidiabetic Agents 393 be mon
Page 11 and 12: Oral Antidiabetic Agents 395 sulpho
Page 13 and 14: Oral Antidiabetic Agents 397 Intest
Page 15 and 16: Oral Antidiabetic Agents 399 guanid
Page 17 and 18: Oral Antidiabetic Agents 401 acts i
Page 19 and 20: Oral Antidiabetic Agents 403 sustai
Page 21 and 22: Oral Antidiabetic Agents 405 chrome
Page 23 and 24: Oral Antidiabetic Agents 407 prepar
Page 25: Oral Antidiabetic Agents 409 On the

Oral Antidiabetic Agents - Luzimar Teixeira

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?